Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Sacubitril/Valsartan in ACHD with HFrEF
NCT05580510Phase 3Unknown
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Instituto Nacional de Cardiología Ignacio Chávez. Primary endpoints: 3D echocardiographic systemic ventricular end-diastolic volume index at 12 weeks and 3D echocardiographic systemic ventricular end-systolic volume index at 12 weeks. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05580510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580510.